MX2010007546A - Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa. - Google Patents

Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.

Info

Publication number
MX2010007546A
MX2010007546A MX2010007546A MX2010007546A MX2010007546A MX 2010007546 A MX2010007546 A MX 2010007546A MX 2010007546 A MX2010007546 A MX 2010007546A MX 2010007546 A MX2010007546 A MX 2010007546A MX 2010007546 A MX2010007546 A MX 2010007546A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitor
akt protein
cyclopentane
hydroxylated
Prior art date
Application number
MX2010007546A
Other languages
English (en)
Inventor
Jun Liang
James F Blake
Ian S Mitchell
Rui Xu
Dengming Xiao
Brian Safina
Birong Zhang
Christine Chabot
Steven Do
Nicholas C Kallan
Josef Bencsik
Keith L Spencer
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2010007546A publication Critical patent/MX2010007546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención provee un compuesto, y sus sales aceptables para uso farmacéutico, que comprenden la Fórmula I: (ver fórmula (I)) Además se proveen métodos para utilizar el compuesto de esta invención como inhibidores de la AKT proteína quinasa y para el tratamiento de enfermedades hiperproliferativas, tal como cáncer.
MX2010007546A 2008-01-09 2009-01-09 Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa. MX2010007546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2008708P 2008-01-09 2008-01-09
PCT/US2009/030602 WO2009089453A1 (en) 2008-01-09 2009-01-09 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2010007546A true MX2010007546A (es) 2010-09-30

Family

ID=40386151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007546A MX2010007546A (es) 2008-01-09 2009-01-09 Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.

Country Status (20)

Country Link
US (1) US8853216B2 (es)
EP (1) EP2240455B1 (es)
JP (1) JP5539225B2 (es)
KR (1) KR101624752B1 (es)
CN (1) CN101932565B (es)
AU (1) AU2009204019B2 (es)
BR (1) BRPI0907372A2 (es)
CA (1) CA2711692A1 (es)
CO (1) CO6280510A2 (es)
CR (1) CR11591A (es)
EC (1) ECSP10010392A (es)
ES (1) ES2401685T3 (es)
HK (1) HK1149269A1 (es)
IL (1) IL206607A0 (es)
MA (1) MA32343B1 (es)
MX (1) MX2010007546A (es)
NZ (1) NZ586720A (es)
RU (1) RU2520735C2 (es)
UA (1) UA100544C2 (es)
WO (1) WO2009089453A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
KR20150089099A (ko) * 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5608097B2 (ja) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピロロピリジン
WO2009089462A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
JP5608098B2 (ja) 2008-01-09 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピラゾロピリジン
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
KR20220139440A (ko) 2013-11-15 2022-10-14 에프. 호프만-라 로슈 아게 피리미딘일사이클로펜테인 화합물의 제조 방법
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885035A (en) * 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) * 1974-02-21 1976-06-29 Pfizer Inc. Piperazino quinazoline bronchodilators
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
JPS562968A (en) * 1979-06-21 1981-01-13 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
US4749704A (en) 1985-03-07 1988-06-07 Sankyo Company Limited Cyclopenta[d]pyrimidine derivatives and use as antidepressants
MX19185A (es) * 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
JP2932693B2 (ja) * 1992-10-05 1999-08-09 宇部興産株式会社 ピリミジン化合物
WO1995003286A1 (fr) 1993-07-23 1995-02-02 The Green Cross Corporation Derive de triazole et son utilisation pharmaceutique
GB9416189D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
US5750531A (en) * 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7067664B1 (en) * 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
DE69836378T2 (de) 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
EP1067123B1 (en) * 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6696440B1 (en) 1999-01-07 2004-02-24 Warner-Lambert Company Treatment of asthma with MEK inhibitors
CA2358438A1 (en) 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
EA200100773A1 (ru) 1999-01-13 2002-02-28 Варнер-Ламберт Компани Замещенные 1-гетероциклические диариламины
CZ20012498A3 (cs) 1999-01-13 2002-08-14 Warner-Lambert Company Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK
AU2483400A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 4'heteroaryl diarylamines
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
ES2251851T3 (es) * 1999-01-13 2006-05-01 Warner-Lambert Company Llc Acidos sulfohidroxamicos y sulfohidroxamatos y su uso com inhibidores mek.
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CN1365277A (zh) 1999-07-16 2002-08-21 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
WO2001005392A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
TR200200204T2 (tr) 1999-07-16 2002-11-21 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2420003A1 (en) 2000-08-25 2002-03-07 Derick Dale Winkle Process for making n-aryl-anthranilic acids and their derivatives
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
HUP0304054A2 (hu) * 2001-04-30 2004-04-28 Glaxo Group Limited A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
US7223738B2 (en) * 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
JP4394961B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤としての融合キノキサリン誘導体
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
MXPA04011093A (es) * 2002-05-10 2005-02-14 Neurocrine Biosciences Inc Piperazina sustituida como ligandos de receptores de melanocortina.
WO2004041162A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20040099681A1 (en) * 2002-11-21 2004-05-27 Nice-Pak Products, Inc. Non-planar dispenser for articles
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CA2522430A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
AU2004263515A1 (en) 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
JP2007501821A (ja) * 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体
CA2538026A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Crf antagonists and heterobicyclic compounds
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
EP1750727A2 (en) * 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
CA2609126A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
AR056691A1 (es) 2005-10-13 2007-10-17 Glaxo Group Ltd Derivados pirrolopirimidina como inhibidores de syk
JP2009523701A (ja) 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
US20090124610A1 (en) 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
CA2656566C (en) * 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
GB0613518D0 (en) 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101516891B (zh) * 2006-07-06 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
SI2049500T1 (sl) * 2006-07-06 2012-01-31 Array Biopharma Inc Ciklopenta (d) pirimidini kot AKT protein kinazni inhibitorji
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
KR20140016431A (ko) 2006-07-06 2014-02-07 글락소 그룹 리미티드 Ｐ２ｘ７­수용체 길항제로서의 치환된 ｎ­페닐메틸­５­옥소­프롤린­２­아미드 및 그의 사용 방법
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
PT2044056E (pt) 2006-07-14 2012-12-05 Novartis Ag Derivados de pirimidina como inibidores de alk-5
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
KR20150089099A (ko) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
WO2009006569A1 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors

Also Published As

Publication number Publication date
RU2520735C2 (ru) 2014-06-27
NZ586720A (en) 2012-11-30
WO2009089453A9 (en) 2009-11-05
EP2240455B1 (en) 2012-12-26
CO6280510A2 (es) 2011-05-20
AU2009204019B2 (en) 2014-02-20
ES2401685T3 (es) 2013-04-23
EP2240455A1 (en) 2010-10-20
BRPI0907372A2 (pt) 2015-07-14
RU2010132912A (ru) 2012-02-20
WO2009089453A1 (en) 2009-07-16
JP2011509306A (ja) 2011-03-24
US8853216B2 (en) 2014-10-07
ES2401685T8 (es) 2014-11-06
US20100292244A1 (en) 2010-11-18
CN101932565B (zh) 2013-06-12
KR20100103865A (ko) 2010-09-28
JP5539225B2 (ja) 2014-07-02
UA100544C2 (ru) 2013-01-10
MA32343B1 (fr) 2011-06-01
IL206607A0 (en) 2010-12-30
CN101932565A (zh) 2010-12-29
CR11591A (es) 2010-11-30
AU2009204019A1 (en) 2009-07-16
HK1149269A1 (en) 2011-09-30
KR101624752B1 (ko) 2016-05-26
ECSP10010392A (es) 2010-09-30
CA2711692A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
IN2014KN02886A (es)
WO2009006567A3 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
MX2010007546A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
MX2009014013A (es) Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
MY147628A (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
TN2011000293A1 (en) Protein kinase inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
MX346186B (es) Inhibidores de proteina cinasas.
WO2011079230A3 (en) Heterocyclic compounds as janus kinase inhibitors
UA104410C2 (uk) Піримідилциклопентани як інгібітори протеїнкіназ акт
MX2012006897A (es) Compuestos heterociclicos como inhibidores de janus cinasa.
GB2499154A (en) Pyrrolo [2,1-c][1,4] naphthodiazepine linked piperazine compounds and a process for the preparation therof

Legal Events

Date Code Title Description
FG Grant or registration